Dr. Zhao Zhigang’s clinical practice and research activities are entirely focused on the pharmacological treatment of serious oncological and hematological malignancies, including the latest approaches in immunotherapy, targeted therapy, and gene and cell therapy. He is Discipline Leader at the medical oncology department at a leading hospital in Tianjin, one of China’s largest metropolitan cities, and a Tier-1 Principal Investigator at the National Cancer Center. His academic and practical background includes medical training at Hebei University, a doctoral degree from Huazhong University of Science and Technology, postdoctoral training at the Indiana University School of Medicine (USA), and more than 25 years of experience at most prominent national cancer research and treatment centers.
Main research areas:
epigenetic mechanisms of hematologic malignancies;
immunotherapy of hematologic malignancies;
hematopoietic stem cell transplantation.
Research project participation:
4 National Natural Science Foundation of China projects (Principal Investigator).
2 Tianjin Natural Science Foundation projects (Principal Investigator).
1 NSFC Young Scientists Fund project and 1 NSFC General Program project (Project Lead), completed.
1 National Key Discipline sub-project and 1 State Key Laboratory open project (Project Lead), completed.
Zhao Zhigang is author/corresponding author of more than 40 SCI papers in international journals including Nature Communications, Cell Reports, Trends in Molecular Medicine, Leukemia, and Oncogene.
A whole series of these publications centered on epigenetic targeted therapy for lymphoma and prognostic stratification of NK/T-cell lymphoma.
Honors and awards:
Provincial/ministerial-level Second Prize, Science and Technology Progress Award
Review expert, National Natural Science Foundation of China (multiple terms)
Academic and professional memberships:
Tianjin Distinguished Professor; Tier-1 Principal Investigator, National Cancer Center; Member, American Association
for Cancer Research (AACR); Member, American Society of Hematology (ASH)
Standing Committee Member, Cancer Rehabilitation Committee, Chinese Association of Rehabilitation Medicine
Reviews